EpimAb Biotherapeutics | ApexOnco - Clinical Trials news and analysis

x

“OncologyPipeline is my favorite CI tool”

Monika Vogelmann

Head of Market Insights Oncology Europe

Daiichi Sankyo

Click here for more information

Conferences Trial results

11 November 2024

ASH 2024 preview – multiple myeloma in focus

AbbVie looks to justify its faith in TeneoOne, and Bristol its phase 3 move with BMS-986393.

Subscribe to EpimAb Biotherapeutics